← All trials
NCT05342792
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Apr 17, 2022
- Primary completion
- Jun 30, 2027
- Completion date
- Jun 30, 2029
- First posted
- Apr 25, 2022
- Last posted
- Apr 25, 2022
- Enrollment
- 556
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Sun Yat-Sen UniversityLead sponsor
- Huazhong University of Science and TechnologyCollaborator
- Huazhong University of Science and TechnologyCollaborator
- Central South UniversityCollaborator
- Central South UniversityCollaborator
- First People's Hospital of FoshanCollaborator
- Guangxi Medical UniversityCollaborator
- Nanjing UniversityCollaborator
- Shandong Provincial HospitalCollaborator
- Wuhan UniversityCollaborator
- Chongqing Medical UniversityCollaborator
- Sun Yat-Sen UniversityCollaborator
- Sun Yat-Sen UniversityOverall official - principal investigator
- Sun Yat-Sen UniversityReponsible party - principal investigator
- Guizhou Medical UniversityCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.